VEGFA and eye disorder: The overall economic burden of major eye disorders in the US is estimated to be more than $35 billion among adults >40 years alone, only 46% of which is attributable to direct medical costs.[20] Our cost estimates do not capture direct nonmedical costs or indirect costs, which are likely to be substantial for POHS patients with CNV-associated vision impairment, as has been previously shown for patients with AMD.[21] Specifically, we found that the costs associated with anti-VEGF treatments were high, with some patients receiving many injections during the study window.